The in vitro activity of the dual-action antibacterial agent Ro 23-9424 was compared with those of cefotaxime, ceftazidime, ciprofloxacin, fleroxacin, imipenem, and amikacin against 358 aerobes and anaerobes. Ro 23-9424 is a new dual-action agent in which a cephalosporin moiety with the same 7-acylamino substituent as ceftriaxone and cefotaxime is linked by an ester bond to the quinolone fleroxacin at the 3'-methyl position. This dual action antibacterial agent is one of a series of cephalosporins with quinolones esterified at the 3' position (H.
Ro 23-9424 is a new dual-action agent in which a cephalosporin moiety with the same 7-acylamino substituent as ceftriaxone and cefotaxime is linked by an ester bond to the quinolone fleroxacin at the 3'-methyl position. This dual action antibacterial agent is one of a series of cephalosporins with quinolones esterified at the 3' position (H. A. Albrecht, G. Beskid, K.-K. Chan, J. Christenson, R. Cleeland, K. Deitcher, D. D. Keith, D. Pruess, J. Sepinwall, A. Specian, R. Then, M. Weigele, and K. West, Program Abstr. 28th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 441, 1988) .
The first reported synthesis of a dual-action cephalosporin was by O'Callaghan et al. (9) . Both the intact dual-action cephalosporin and released substituent (omadine) were active in vitro (3, 9) . This dual-action cephalosporin did not materialize as a therapeutic reality due to undesirable toxic properties of omadine (9) . More recently, other investigators (4, 6) reported on a cephalosporin peptide ester which featured an alanine racemase inhibitor at the 3'-methyl position of the cephalosporin. The cephem ester and dipeptide (1, 6) displayed good antibacterial activity against both gram-positive and gram-negative organisms. Subsequent studies (1, 5) suggested that the mechanism of action of the antibacterial dipeptide in gram-negative bacteria involved transport, hydrolysis, and intracellular inactivation of the essential enzyme, alanine racemase.
Our initial studies with Ro 23-9424 demonstrated that this new agent had a broad spectrum of antibacterial activity in vitro. On the basis of these results, a more extensive investigation was carried out with Ro 23-9424 in comparison with other broad-spectrum potent antimicrobial agents (i.e., cefotaxime, ceftazidime, ciprofloxacin, fleroxacin, imi- To rank order the activity of each of the agents against three bacterial groups, members of the family Enterobacteriaceae, Pseudomonas and Acinetobacter spp., and the gram-positive cocci, all of the strains in each group were utilized to determine the MIC90s.
All of the agents were highly active against the majority of Enterobacteriaceae members tested. Based on MICgs (micrograms per milliliter), the order of activity against members of the Enterobacteriaceae was as follows: ciprofloxacin, 0.063; Ro 23-9424, fleroxacin, and imipenem, 0.5; ceftazidime, 2; amikacin, 4; and cefotaxime, 16. Based on the percentage of strains susceptible at the breakpoints utilized, the Enterobacteriaceae members were highly susceptible to all agents with the following exceptions: only 65% of Citrobacter spp. were susceptible to ceftazidime and cefotaxime, 60% of Shigella spp. were susceptible to amikacin, and 55% of Serratia spp. were susceptible to cefotaxime. The organisms in this group were most susceptible overall to ciprofloxacin and Ro 23-9424.
The activities of the seven agents against both the Pseu- 
